A Virtual Forum Designed to Solve Clinical Challenges and Improve Patient Outcomes 

August 4, 2021 – August 6, 2021

swoosh
swoosh

AGENDA

 

ENHANCE YOUR EXPERIENCE WITH MEDCHALLENGE!

This event features MedChallenge, a new feature from Medscape that allows you to go head-to-head against your peers in a series of medical questions. Take a chance to win a donation to the charity of your choice. Earn points, deepen your knowledge, and fight for the top spot on the leaderboard!

MORE DETAILS COMING SOON!

 *All sessions listed in Eastern time. Agenda subject to change.

LEARNING OBJECTIVES

Upon completion of this session, learners will have

  • Increased knowledge regarding
    • The clinical trial data evaluating targeted therapies for patients with NSCLC
  • Greater competence related to
    • Utilizing diagnostic methodologies to identify molecular alterations in patients with NSCLC
    • Personalizing therapy for patients with NSCLC and molecular alterations
    • Mitigating treatment-related adverse events in patients receiving targeted therapy for NSCLC
  • Greater confidence in their ability to
    • Communicate treatment considerations with patients with NSCLC and molecular alterations

CO-CHAIR


 

 *All sessions listed in Eastern time. Agenda subject to change.

LEARNING OBJECTIVES

Upon completion of this session, learners will have

  • Increased knowledge regarding
    • Clinical trial data evaluating immunotherapy as treatment for patients with NSCLC
  • Greater competence related to
    • Selecting the most appropriate immunotherapy-containing regimen for a patient with NSCLC
    • Managing irAEs in patients receiving immunotherapy for NSCLC
  • Greater confidence in their ability to
    • Communicate treatment considerations with the interprofessional team

CO-CHAIR


 

 *All sessions listed in Eastern time. Agenda subject to change.

LEARNING OBJECTIVES

Upon completion of this session, learners will have

  • Increased knowledge regarding the
    • Rationale for utilizing systemic treatment in patients with early-stage NSCLC
    • Key data from clinical trials evaluating systemic treatment in patients with early-stage NSCLC

CO-CHAIR


 

 *All sessions listed in Eastern time. Agenda subject to change.

LEARNING OBJECTIVES

Upon completion of this session, learners will have

  • Increased knowledge regarding the
    • Role of various team members in the management of patients with NSCLC
    • Clinical trial data evaluating regimens used for the treatment of patients with SCLC
  • Greater competence related to
    • Tailoring therapy for patients with SCLC
    • Identifying potential treatment-related AEs in patients receiving therapy for SCLC
  • Greater confidence in their ability to
    • Leverage the use of the interprofessional team in order to optimize outcomes in patients with SCLC

CO-CHAIR


 

 *All sessions listed in Eastern time. Agenda subject to change.

LEARNING OBJECTIVES

Upon completion of this session, learners will have

  • Increased knowledge regarding
    • The characteristics that prompt suspicion of a mesothelioma diagnosis
  • Greater competence related to
    • Individualizing therapy for patients with mesothelioma
  • Greater confidence in their ability to
    • Effectively communicate aspects of care with patients with mesothelioma

CO-CHAIR


 

 *All sessions listed in Eastern time. Agenda subject to change.

LEARNING OBJECTIVES

Upon completion of this session, learners will have

  • Increased knowledge regarding
    • Importance of early lung cancer detection and screening 
    • Clinical trial data evaluating screening and early detection methods
  • Greater confidence in their ability to
    • Incorporate strategies into clinical practice that may improve early detection of lung cancer

CO-CHAIR


 

 *All sessions listed in Eastern time. Agenda subject to change.

LEARNING OBJECTIVES

Upon completion of this session, learners will have

  • Increased knowledge regarding
    • The clinical trial data evaluating targeted therapies for patients with NSCLC
  • Greater competence related to
    • Utilizing diagnostic methodologies to identify molecular alterations in patients with NSCLC
    • Personalizing therapy for patients with NSCLC and molecular alterations
    • Mitigating treatment-related AEs in patients receiving targeted therapy for NSCLC
  • Greater confidence in their ability to
    • Communicate treatment considerations with patients with NSCLC and molecular alterations

CO-CHAIR